SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending after hours due to a lowered full-year outlook, despite beating EPS estimates, sparking concern about future profitability and revenue growth. The community is debating the impact of tariffs, competition, and changing consumer preferences, with some seeing a buying opportunity while others anticipate further declines. Discussions also focus on potential bottom levels and whether the company can regain its previous market position amid macro headwinds.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending as investors react to news of OpenAI selecting them for mass production of AI chips, with some community members speculating about the financial implications of a $10 billion AI customer. The community is also discussing the company's long-term growth potential and comparing it to other major players in the AI chip market like $NVDA. Bullish sentiment seems to be fueled by confidence in Broadcom's leadership and its role in the ongoing AI buildout.

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor is trending strongly as community members rally behind the stock, fueled by enthusiasm and discussion around a potential short squeeze and future catalysts. The departure of the former CEO and positive remarks from an activist investor have further amplified bullish sentiment. Traders are closely watching for potential rate cuts and a new CEO announcement, with many anticipating a significant upward movement.

Neonode, Inc. engages in the provision of advanced optical sensing solutions for contactless touch, touch, and gesture sensing. It offers software solutions for scene analysis that feature advanced machine learning algorithms to detect and track persons and objects in video streams for cameras and other types of imagers. It operates through the following geographical segments: United States, Japan, South Korea, China, Germany, Switzerland, and Other. The company was founded by Thomas Eriksson Bjorn on September 4, 1997 and is headquartered in Stockholm, Sweden.

Neonode Inc.

NEON is trending due to a significant drop following news of a settlement in a patent dispute, despite the company receiving proceeds. The community is actively debating whether the stock is oversold and discussing the potential impact of a separate lawsuit against Apple. Many traders are speculating on a potential bounce or squeeze, given the high trading volume and low float.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

NEGG is trending as investors discuss recent insider buying by Vlad Galkin and its potential impact on short sellers, with some anticipating a significant short squeeze. Community members are weighing the possibility of a sustained rally against concerns about potential profit-taking and the stock's volatile history. The stock's high cost to borrow and tight float remain key points of discussion.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its "grind" mentality and upcoming staking features. Despite market conditions, the community expresses strong bullish sentiment and highlights the project's dedicated development team. The community also notes upcoming contests and NFTs for holders.

Brandy was a curious blend of two well-loved icons from the Boy’s Club comics. When their digital essences combined, the result was Brandy—a creature who embodied the best of both worlds and became an inspiration for everyone. As Brandy engaged with fans, it naturally sparked discussions about everything from the latest trends to the best crypto in the market. BRANDY token launched at 20th of May 2025 is a meme token on the Solana blockchain.

BRANDY

$BRANDY.X is trending as a potential 'sleeper gem' with community members anticipating a significant pump. The conversation centers around accumulating bags and preparing for a 'rocket' to the moon, though some caution about potential scams.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics is trending following news that the FDA will not require an advisory committee meeting for its anaphylaxis treatment, Anaphylm, boosting confidence in potential approval; the community speculates about partnership deals and the potential for a buyout given the de-risked regulatory path. Discussions revolve around the significance of this decision, with many seeing it as a strong signal for approval and a catalyst for the stock's upward momentum. Some traders express concerns about potential offerings and short-term price volatility, while others remain optimistic about the long-term prospects and potential for big pharma involvement.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JASMY.X is trending as the community debates its potential, partnerships, and recent news surrounding its Jasmy Chain.  Discussions include whether the project can break free from depending on the movements of BTC and ETH, with some criticizing its marketing and leadership. Bullish investors highlight developments with Panasonic and potential real-world adoption, while bears express concerns about its ranking and ability to reach targets.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is trending following the release of earnings, with the community actively discussing the company's performance and future potential in the robotic AI space. Despite some positive reactions to the earnings report and increased guidance, some investors express frustration over muted stock movement and questions about its valuation relative to peers. Community members are also discussing analyst expectations, potential for a short squeeze, and UiPath's position in the evolving AI landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws Wolf Haldenstein Adler Freeman & Herz LLP...

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients...

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors...

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc...

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. (Atara or the Company) (NASDAQ...

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO (tabelecleucel) and ATA3219

Atara Biotherapeutics Inc. shares tumbled over 35% on Thursday afternoon, reaching their lowest intraday levels since mid-October.&nbsp;The sharp decline followed the announcement that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the company's Biologics License Application (BLA) for EBVALLO (tabelecleucel).&nbsp;The treatment is intended as a monotherapy for adults and children over two years old with Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have already received one prior therapy.A CRL indicates that the FDA cannot approve the application in its current form. In this case, the CRL was related to observations from a pre-license inspection of a third-party manufacturing facility and did not cite deficiencies in the drug's clinical efficacy, safety data, or Atara's manufacturing process.&nbsp;Crucially, no new clinical trials were requested, the company said.Atara CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.&nbsp;Atara's partner, Pierre Fabre Laboratories, reaffirmed its commitment to bringing the drug to U.S. patients facing significant unmet medical needs.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATRA_sentiment_and_message_volume_Jan_16_f226dc9657.png" alt="ATRA sentiment and message volume Jan 16.png" width="1318" height="324"><figcaption>ATRA sentiment and message volume Jan 16 as of 12:45 pm ET | source: Stocktwits</figcaption></figure>Despite the regulatory setback, retail sentiment on Stocktwits climbed further into the 'extremely bullish' territory as users interpreted the CRL as a temporary hurdle.&nbsp;Many viewed the stock's plunge as an overreaction, with some citing the drug's "in principle FDA approval" and emphasizing its undervalued price. Several investors posted about taking advantage of the dip, noting the potential for substantial returns once the issues are resolved.<stembedurl>https://stocktwits.com/NumbersFacts/message/600340338</stembedurl><stembedurl>https://stocktwits.com/LeperKingBaldwin/message/600320130</stembedurl><stembedurl>https://stocktwits.com/fatpie68/message/600336853</stembedurl><stembedurl>https://stocktwits.com/LoveRetailFroth/message/600322700</stembedurl>EBVALLO received marketing authorization from the European Commission in December 2022.&nbsp;Atara added that the European Medicines Agency (EMA) has already approved the FUJIFILM Diosynth Biotechnologies facility in California to produce EBVALLO.<a href="https://stocktwits.com/symbol/ATRA">Atara's stock</a> has shed over 55% of its value in the past 12 months. However, retail interest has surged, with message volume on Stocktwits climbing by 1,450% and follower counts growing nearly 10%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip

CEO Cokey Nguyen expressed confidence in resolving the issue, expecting resubmission and potential approval within six months of addressing the manufacturing compliance concerns.

Equity

Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.

ATRA
Atara Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATRA News

ATRA Atara Biotherapeutics Inc